Genprex Inc

NASDAQ:GNPXUnited States

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogen therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a multifunctional gene that helps in cancer suppression and normal cell regulation. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Contact Information

Headquarters

Suite 3.322 1601 Trinity Street, Bldg. BAUSTIN, TX, United States 78712

Phone

512-537-7997

Fax

302-655-5049

Executives

Chairman of the Board, President, Co-Founder, Company Secretary

J. Rodney Varner

Chief Financial Officer

Ryan Confer

Executive Vice President, General Counsel, Chief Strategy Officer

Catherine Vaczy

Chief Manufacturing and Technology Officer

Hemant Kumar

Chief Medical Officer

Mark Berger